A delegation of senior representatives from Evonik Venture Capital arm of Evonik Industries visited Israel technological and scientific university in Haifa, the Technion, as part of the firm’s exposure campaign (Roadshow) to Israel. Dr. Peter Nagler, Head International Innovation and Dr. Bernhard Mohr, Managing Director Venture Capital, met with the Technion Research and Development Foundation’s Business Unit Manager, Benjamin Soffer, and Prof. Noam Adir, Deputy Executive Vice President for Research, to discuss possibilities for future cooperation with the Technion.
“We are interested in discussing possibilities for cooperation particularly in regard to venture capital but also from a general R&D perspective, ” said Nagler. “We collaborate with several universities around the world and consider Technion as a most desirable potential partner. The purpose of our meeting is to present Evonik while learning more about the Technion, and to start discussing potential areas of synergy and possibilities for cooperation.”
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Evonik Industries AG is a multinational specialty chemical manufacturer serving the automotive, plastics, pharmaceutical, and other industries, and employing over 30, 000 people. The company’s sales volume is roughly €13 billion a year. Evonik Venture Capital, founded in 2012, is the investment arm of Evonik Industries. The company is active in more than 100 countries globally and invests in start-up companies and VC funds, with a preference for innovative technological companies characterized by high growth potential in areas such as specialty chemicals, advanced materials, nanotechnology, cleantech, biotechnology and medical technology. Evonik has earmarked €100 million for invest in such companies.
The company maintains close ties with a number of venture capital funds and organizations in Israel, but has not made any investments in Israel to date. During this visit, the delegation will meet with Israeli start-ups, venture capital firms and representatives from government, as well as with the Director of the Chief Scientist Office from the Ministry of Economy, Mr. Avi Hasson.
